GlassScriptPhysician profile
Dhruv M Amin
NPI 1043520398
$5,412.46
in general payments reported to CMS, 2019-2025
29 companies · $775 in 2025
The $775 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $719 · 2021: $1,554 · 2022: $603 · 2023: $505 · 2024: $819 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.41 |
| Education | $235.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $933.74 | 2020-2025 | Viberzi, Linzess, Vraylar |
| Astrazeneca Pharmaceuticals LP | $834.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $658.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $608.22 | 2020-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $456.30 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.40 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $198.97 | 2019-2022 | |
| Glaxosmithkline, LLC. | $178.65 | 2019-2021 | |
| Pfizer INC. | $173.50 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $148.44 | 2020-2023 | Ztlido |
| Amgen INC. | $123.41 | 2020-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $102.70 | 2019-2021 | |
| Horizon Therapeutics Plc | $75.73 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $59.86 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $57.18 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $53.98 | 2025 | Auvelity |
| Allergan, INC. | $50.75 | 2019-2020 | |
| Amarin Pharma, INC. | $33.65 | 2020-2021 | |
| Phadia US INC. | $31.96 | 2023-2025 | Immunocap |
| Exact Sciences Corporation | $31.95 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.72 | 2019 | |
| Genentech USA, INC. | $28.19 | 2020-2021 | |
| Esperion Therapeutics, INC. | $27.95 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $17.86 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $17.29 | 2024 | Voquezna |
| Arbor Pharmaceuticals, INC. | $16.70 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.56 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $15.00 | 2025 | Korlym |
| Shield Therapeutics INC | $13.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhruv Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.